RedHill Biopharma

329 articles with RedHill Biopharma

• 

  BioSpace Global Roundup, Oct. 15

  10/15/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections

  10/14/2020

  RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks -- Orphan Drug Designation , along with RHB-204’s FDA QIDP priority designation, will extend U.S. potential market exclusivity to a total of 12 years TEL AVIV, Israel and RALEIGH, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the U.S. Food and Dr

• RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib

  10/13/2020

  Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthen s manufacturing capabilities and capacity , in preparation for potential emergency use applications  --        Enrollment in the g lobal Phase 2/3 COVID-19 study with opaganib is advancing rapidly following approval s in 6 countries -- U.S . Phase 2 COVID-19 study with opaganib

• 

  BioSpace Global Roundup, Oct. 8

  10/8/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review

  10/7/2020

  Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19  -- The U.S. Phase 2 study is 75% enrolled with data expected later this quarter -- In parallel, e nrollment advancing rapidly in the g lobal COVID-19 P hase 2/3 study with opaganib  -- Global emergency use authorization applications are planned, subject t

• RedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual Conferences

  10/6/2020

  RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will present at the following virtual conferences in October:

• 

  BioSpace Global Roundup, Sept. 24

  9/24/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

• Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data

  9/23/2020

  Veeva Vault CDMS and Bioforum selected to optimize clinical data management for RedHill’s global Phase 2/3 clinical trial evaluating opaganib in patients with severe COVID-19

• 

  Biopharma Update on the Novel Coronavirus: September 23

  9/23/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.

• Brazil Approves RedHill Biopharma’s Phase 2/3 COVID-19 Study with Opaganib

  9/22/2020

  RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing global Phase 2/3 study evaluating opaganib1 in patients hospitalized with severe COVID-19 pneumonia.

• 

  BioSpace Global Roundup, Sept. 10

  9/10/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• RedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events

  9/9/2020

  RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that RedHill’s Chief Executive Officer, Dror Ben-Asher, will present at the Morgan Stanley Annual Global Healthcare Conference, on Thursday, September 17, 2020.

• 

  Biopharma Update on the Novel Coronavirus: September 9

  9/9/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.

• RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2

  9/8/2020

  Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study -- Opaganib is uniquely positioned as an orally-administered potential COVID-19 treatment combining potent antiviral and anti-inflammatory mechanisms of actio n, targeting a host cell component and minimizing likelihood of resistance -- Global Phase 2/3 and U.S. Phase 2

• RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania

  9/3/2020

  A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with dual anti-inflammatory and anti-viral properties

• RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy

  8/27/2020

  A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and enrollment is planned to be completed in the coming weeks

• RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights

  8/13/2020

  Q2/2020 net revenues of approximately $21 million, up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively

• RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products

  8/13/2020

  RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. for an exclusive licensing and manufacturing agreement for multiple products.

• RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico

  8/6/2020

  The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites

• RedHill Biopharma to Participate in Upcoming BTIG and Intellisight Conferences

  8/5/2020

  RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will participate in the following virtual conferences in August